Kolosis BIO, LLC (Kolosis) announced today, in collaboration with MTF Biologics (MTF), the market release of Kore Fiber™, an exclusively processed demineralized cortical fiber allograft for Kolosis.
Dr. Anthony Russo, of Montana Orthopedics in Butte, Montana stated, “The aseptic processing methods coupled with the fantastic handling characteristics of Kore provide an excellent option for bone grafting. I am a believer in the power of MTF allografts to help accelerate bone healing for my patients.” Dr. Russo was the first surgeon nationwide to implant Kore and incorporate the tissue into his practice.
Kolosis President and Chief Executive Officer Collin Begley noted, “We are extremely excited to launch Kore Fiber with MTF Biologics. Based on our commercial experience in bone grafting technologies, especially with MTF processed tissues, we see the enormous potential of this tissue form to capture significant market share in the cortical fiber space. Kore is an aseptically-processed, 100% cortical bone matrix with tremendous handling characteristics. Extensive pre-launch testing confirms Kore’s dynamic spectrum of growth factors; attributes which are essential for promoting and accelerating bone healing. We could not be more excited to add Kore Fiber to our exclusive MTF portfolio of bone graft tissues, which also includes Prime HD®, a pre-hydrated cortical graft.”
Chief Executive Officer of the MTF Biologics Joe Yaccarino commented, “Our long-term commercial experience with the team at Kolosis has proven to be extremely successful for MTF, and we’re proud to launch Kore as an extraordinary graft option to tissue recipients.”
The release of Kore Fiber includes the launch into both spinal and orthopedic applications and is available in four different sizes of moldable fiber and three sizes of strips.
About Kolosis BIO:
Kolosis BIO is a rising biologics pure-play, dedicated to commercializing cutting-edge technologies to multiple verticals in the surgical biologics space. With a proven track record of scaling market-leading technologies, Kolosis is dedicated to driving innovation and pushing the boundaries of science to enhance patient outcomes. With a focus on providing bold technologies and relentless execution, Kolosis has become a leading force in the surgical biologics market. For more information, please visit www.kolosis.com.
About MTF Biologics:
MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. It provides unmatched service, resources and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers and clinicians and scientists.
The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized screening, coordination, and communications services to organ transplant centers, organ, tissue, and eye procurement organizations, and the hospitals and patients that they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation) expands its reach to patients across the globe. For more information, please visit www.mtfbiologics.org.
